Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person E3 ubiquitin-protein ligase parkin (PRKN, also known as PARK...
| Class:Id | Summation:9794179 |
|---|---|
| _displayName | E3 ubiquitin-protein ligase parkin (PRKN, also known as PARK... |
| _timestamp | 2022-06-27 16:30:17 |
| created | [InstanceEdit:9794178] Shamovsky, Veronica, 2022-06-27 |
| literatureReference | [LiteratureReference:9793492] The AMPK-Parkin axis negatively regulates necroptosis and tumorigenesis by inhibiting the necrosome |
| text | E3 ubiquitin-protein ligase parkin (PRKN, also known as PARK2), was shown to negatively regulate necroptosis in human and mouse cells through promoting K33-linked polyubiquitination of receptor-interacting protein 3 (RIPK3) (Lee SB et al. 2019). PRKN-catalyzed polyubiquitination of RIPK3 at K197, K302 or K364 decreased RIPK1:RIPK3-mediated necroptosis in human colorectal adenocarcinoma HT-29 cells in response to T/C/Z treatment (TNF-ɑ with cycloheximide and the caspase inhibitor zVAD (Z)) (Lee SB et al. 2019). |
| (summation) | [BlackBoxEvent:9793485] PRKN polyubiquitinates RIPK3 [Homo sapiens] |
| [Change default viewing format] | |
No pathways have been reviewed or authored by E3 ubiquitin-protein ligase parkin (PRKN, also known as PARK... (9794179)
